Bausch Company Profile
What is the competitive landscape for BAUSCH
BAUSCH has one hundred and eighty-seven approved drugs.
There are one hundred and fourteen US patents protecting BAUSCH drugs.
Summary for Bausch
| US Patents: | 114 |
| Tradenames: | 160 |
| Ingredients: | 125 |
| NDAs: | 187 |
| Patent Litigation for Bausch: | See patent lawsuits for Bausch |
Drugs and US Patents for Bausch
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch | JUBLIA | efinaconazole | SOLUTION;TOPICAL | 203567-001 | Jun 6, 2014 | AB | RX | Yes | Yes | 9,566,272 | ⤷ Start Trial | ⤷ Start Trial | |||
| Bausch | BENZACLIN | benzoyl peroxide; clindamycin phosphate | GEL;TOPICAL | 050756-001 | Dec 21, 2000 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Bausch | LOCOID | hydrocortisone butyrate | SOLUTION;TOPICAL | 019116-001 | Feb 25, 1987 | AT | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ||||
| Bausch | APLENZIN | bupropion hydrobromide | TABLET, EXTENDED RELEASE;ORAL | 022108-003 | Apr 23, 2008 | RX | Yes | Yes | 7,585,897 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Bausch
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bausch | CARDIZEM CD | diltiazem hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 020062-001 | Aug 10, 1992 | 5,286,497 | ⤷ Start Trial |
| Bausch | APLENZIN | bupropion hydrobromide | TABLET, EXTENDED RELEASE;ORAL | 022108-003 | Apr 23, 2008 | 7,662,407 | ⤷ Start Trial |
| Bausch | APLENZIN | bupropion hydrobromide | TABLET, EXTENDED RELEASE;ORAL | 022108-002 | Apr 23, 2008 | 7,662,407 | ⤷ Start Trial |
| Bausch And Lomb Inc | XIIDRA | lifitegrast | SOLUTION/DROPS;OPHTHALMIC | 208073-001 | Jul 11, 2016 | 9,216,174 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for BAUSCH drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Gel | 0.77% | ➤ Subscribe | 2006-05-10 |
| ➤ Subscribe | Cream | 5% | ➤ Subscribe | 2006-10-17 |
| ➤ Subscribe | Extended-release Tablets | 174 mg | ➤ Subscribe | 2009-09-28 |
| ➤ Subscribe | Cream | 0.10% | ➤ Subscribe | 2008-01-31 |
| ➤ Subscribe | Extended-release Tablets | 522 mg | ➤ Subscribe | 2009-12-24 |
| ➤ Subscribe | Cream | 2.5% | ➤ Subscribe | 2014-06-17 |
| ➤ Subscribe | Extended-release Tablets | 420 mg | ➤ Subscribe | 2005-04-25 |
| ➤ Subscribe | Rectal Gel | 2.5 mg/0.5 mL, 5 mg/mL, 10 mg/2 mL, 15 mg/3 mL and 20 mg/4 mL | ➤ Subscribe | 2004-03-23 |
| ➤ Subscribe | Extended-release Tablet | 55 mg and 80 mg | ➤ Subscribe | 2010-12-02 |
| ➤ Subscribe | Rectal Gel | 5 mg/mL, 2mL pre-filled syringe | ➤ Subscribe | 2008-12-23 |
| ➤ Subscribe | Extended-release Tablets | 150 mg and 300 mg | ➤ Subscribe | 2004-09-21 |
| ➤ Subscribe | Gel | 1.2%/3.75% | ➤ Subscribe | 2015-09-30 |
| ➤ Subscribe | Ophthalmic Solution | 0.07% | ➤ Subscribe | 2013-07-26 |
| ➤ Subscribe | Gel | 0.04% | ➤ Subscribe | 2010-12-20 |
| ➤ Subscribe | Vaginal Gel | 0.75% | ➤ Subscribe | 2004-09-02 |
| ➤ Subscribe | Capsules | 75 mg | ➤ Subscribe | 2011-06-06 |
| ➤ Subscribe | Topical Solution | 10% | ➤ Subscribe | 2018-06-06 |
| ➤ Subscribe | Lotion | 0.1% | ➤ Subscribe | 2016-08-31 |
| ➤ Subscribe | Extended-release Tablets | 348 mg | ➤ Subscribe | 2009-09-24 |
| ➤ Subscribe | Cream | 3.75% | ➤ Subscribe | 2012-08-08 |
| ➤ Subscribe | Extended-release Tablets | 120 mg, 180 mg, 240 mg, 300 mg and 360 mg | ➤ Subscribe | 2005-08-30 |
| ➤ Subscribe | For Inhalation Solution | 6 gm/vial | ➤ Subscribe | 2014-05-22 |
| ➤ Subscribe | Extended-release Tablets | 65 mg and 115 mg | ➤ Subscribe | 2009-11-19 |
| ➤ Subscribe | Rectal Gel | 5 mg/mL, 4mL pre-filled syringe | ➤ Subscribe | 2008-12-08 |
| ➤ Subscribe | Extended-release Tablet | 105 rng | ➤ Subscribe | 2010-12-28 |
| ➤ Subscribe | Gel | 1.2%/2.5% | ➤ Subscribe | 2012-12-20 |
| ➤ Subscribe | Ophthalmic Solution | 0.5% | ➤ Subscribe | 2012-10-19 |
| ➤ Subscribe | Gel | 0.1% | ➤ Subscribe | 2010-07-08 |
| ➤ Subscribe | Ophthalmic Solution | 1.5% | ➤ Subscribe | 2013-09-09 |
| ➤ Subscribe | Gel | 1.2%/0.025% | ➤ Subscribe | 2010-12-17 |
International Patents for Bausch Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 102158400 | ⤷ Start Trial |
| Argentina | 074802 | ⤷ Start Trial |
| Spain | 2427596 | ⤷ Start Trial |
| Japan | 2014133751 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Bausch Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2822954 | 1890030-8 | Sweden | ⤷ Start Trial | PRODUCT NAME: BICTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BICTEGRAVIR SODIUM; FIRST MARKETING AUTHORIZATION NUMBER SE: EG EU/1/18/1289, 2018-06-25; RAETTAD SKYDDSTID FOER TILLAEGGSSKYDD'; PRV HAR I BESLUT DEN 8 JULI 2025 RAETTAT SKYDDSTIDEN I FOELJANDE TILLAEGGSSKYDD I ENLIGHET MED PMD:S BESLUT PMAE 7804/24: 2290016-1, 2090020-5, 2090055-1, 1590060-8, 1890030-8, 1990012-5, 2190017-0, 1690040-9, 1790035-8, 2390005-3, 1990013-3, 2090009-8 |
| 0799044 | 02C0040 | France | ⤷ Start Trial | PRODUCT NAME: OLOPATADINE HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/02/217/001 20020517 |
| 1856135 | LUC00153 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: FOSTAMATINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE FOSTAMATINIB, OU UN HYDRATE, SOLVATE OU N-OXYDE DE FOSTAMATINIB OU LE SEL PHARMACEUTIQUEMENT ACCEPTABLE DE FOSTAMATINIB, EN PARTICULIER FOSTAMATINIB DISODIUM, EVENTUELLEMENT SOUS FORME D'HYDRATE; AUTHORISATION NUMBER AND DATE: EU/1/19/1405 20200113 |
| 1856135 | SPC/GB20/016 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: FOSTAMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, OR A HYDRATE, SOLVATE OR N-OXIDE OF FOSTAMATINIB OR THE PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, ESPECIALLY FOSTAMATINIB DISODIUM, OPTIONALLY IN FORM OF A HYDRATE; REGISTERED: UK EU/1/19/1405 (NI) 20200113; UK PLGB 12930/0022 20200113; UK PLGB 12930/0023 20200113 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
